The Signal
$AQST and $IOVA earnings (Nov 3-5) operationalize two orthogonal de-risking catalysts: Anaphylm pre-PDUFA traction + KRAS WT biomarker stratification for NSCLC. Simultaneously, Democratic sweep (House + Senate control) freezes Texas/blue-state data center capex, which paradoxically pressures commodity biotech infrastructure but accelerates precision oncology adoption—fewer hyperscale centers = higher willingness to pay for targeted therapeutics with smaller manufacturing footprints. Protein design tools (RFD4-Proteina, BL8 interface calibration) are operationalizing variant prioritization at scale, narrowing candidate risk pools for 2H27 Phase 1 entry. Neither play requires AI hype; both require execution discipline and payer conviction.
What's Moving
- $AQST (Anaphylm pre-PDUFA approval + $2B epinephrine TAM) — Q3 earnings (11/3 AH, call 11/4 8am ET) expected to confirm NDA resubmission momentum + launch hiring (Medical Liaisons, Regional Directors operationalized). Allergy KOL enthusiasm unlocked by CRL resolution; $473M cap vs. $1.8B post-approval floor = 3.8x upside into 1H27. PharmFilm solves 30-year portability problem vs. EpiPen incumbency. (via @biotechscanner)
- $IOVA (KRAS WT precision NSCLC + mDOR durability) — Q3 earnings call 11/5 8:30am ET expected to detail sBLA filing timeline for biomarker-stratified cohort (59.1% ORR second-line, 85.7% + pembro frontline, mDOR ~18 months). Polyclonal TIL moat vs. CAR-T heterogeneity deepens solid-tumor TAM to 7x melanoma; 150+ ATCs operationalized removes valuation ceiling. (via @biotechscanner)
- Protein design operationalizes discovery acceleration — RFD4-Proteina (IPD × NVIDIA diffusion) + BL8 (15,396 curated interface atlas, discrete signatures) + SAbDab2 (ML-ready antibody database, versioned splits) remove data-leakage risk and narrow variant prioritization. Local MacBook deployment (RFD4 port) operationalizes wet-lab validation loop. Attribution ≠ predictive accuracy; models still need Phase 1. (via @biologyaidaily, @allthingsapx)
Crosscurrents
- Data center sector sentiment whipsaw — @biotech2k1 flagging potential derisk of DC stocks post-blue wave (Texas Democratic sweep kills tax credits, power grid access constraints). Paradox: shrinking hyperscale capacity doesn't kill AI; it redirects capex to precision biotech where smaller manufacturing + higher unit economics justify tighter margin profiles. Watch for payer sentiment shift into targeted therapeutics.
- $MDGL whistleblower complaint — Safety allegation surfaced in 10-Q (former employee, Sarbanes-Oxley retaliation claim re: Rezdiffra safety issues). Q3 beat ($431M Rezdiffra sales) intact, but governance risk lingers. Street pricing execution; safety data still solid per earnings. (via @adamfeuerstein)
Tradecraft
Desk Notes
- @biotechscanner — $AQST largest holding + significant $IOVA; conviction on Anaphylm blockbuster TAM + precision TIL NSCLC ceiling; earnings catalysts Nov 3-5.
- @biotech2k1 — $INSM/$BBIO core; trading $MDGL/$MIRM into earnings; sentiment off X as leading indicator; DC stock derisk post-sweep.
- @biologyaidaily — Protein design (RFD4, BL8, SAbDab2) operationalizing variant prioritization; attribution calibration removes confabulation risk; wet-lab validation Q4 2026 gate.